Welcome to our dedicated page for Cyclo Therapeutics news (Ticker: CYTH), a resource for investors and traders seeking the latest updates and insights on Cyclo Therapeutics stock.
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) is a clinical-stage biotechnology company whose news flow centers on the development of its lead investigational product, Trappsol® Cyclo™, for Niemann-Pick Disease Type C1 (NPC1) and early Alzheimer’s disease. News updates commonly highlight progress in the pivotal Phase 3 TransportNPC™ trial, data from clinical sub-studies, and regulatory and intellectual property milestones.
Investors and followers of CYTH can expect clinical trial updates, including completion of enrollment milestones, interim analyses plans, and preliminary safety and efficacy findings from the TransportNPC™ study and its open-label sub-study in very young NPC1 patients. The company frequently reports on presentations at major scientific meetings such as WORLDSymposium™ and the SSIEM Annual Symposium, where it shares poster and oral presentation data on long-term treatment, safety profiles and clinical outcomes.
Cyclo Therapeutics’ news also covers regulatory strategy developments, such as alignment with the U.S. Food and Drug Administration and European Medicines Agency on potential NDA and MAA submissions based on interim Phase 3 data, as well as the impact of Orphan Drug, Fast Track and Rare Pediatric Disease designations. In addition, the company issues updates on its Alzheimer’s disease program, including patent grants in the U.S. and Europe for methods of treating Alzheimer’s disease with Trappsol® Cyclo™ and progress in its Phase 2b trial.
Corporate and financial announcements, including quarterly and annual results, merger activity with entities such as Applied Molecular Transport and agreements with Rafael Holdings, Inc., are also part of the CYTH news stream. Readers who track CYTH news gain insight into the company’s clinical progress, regulatory path, scientific visibility and financing strategy as it advances Trappsol® Cyclo™ in rare disease and neurodegenerative indications.
Cyclo Therapeutics (Nasdaq: CYTH) announced its participation in the 17th Annual WORLD Symposium 2021, a virtual conference focused on lysosomal storage diseases, scheduled from February 8–12, 2021. Key presentations will feature updates on the Trappsol® Cyclo™ clinical trials for Niemann-Pick Disease Type C, with a platform presentation on February 9 by Dr. Julian Raiman and ePosters presented by both Dr. Raiman and Dr. Caroline Hastings. Full details and updates will be available on Cyclo Therapeutics' website post-presentation.
Cyclo Therapeutics (NasdaqCM:CYTH, CYTHW) announced initial data from its open-label study of Trappsol® Cyclo™ for Niemann-Pick Disease Type C (NPC). All eight patients in the study demonstrated disease stability or improvement in NPC Severity Scores over 10 months. Notably, patients receiving 1500 mg/kg showed stable scores, while those at 2500 mg/kg improved significantly. The safety profile was favorable, with only mild adverse events reported. Cyclo Therapeutics has FDA authorization to begin a Phase 3 trial, expected to enroll patients in early 2021, enhancing the company's position in the neurodegenerative disease market.
Cyclo Therapeutics, Inc. (NasdaqCM:CYTH, CYTHW) has completed the sale of an additional 375,000 shares of common stock at $4.99 each, generating gross proceeds of $1,871,250. This affects the public offering that initially closed on December 11, 2020, increasing total proceeds to $14,375,000. Maxim Group LLC served as the sole book-running manager for the offering. The company focuses on cyclodextrin-based treatments for neurodegenerative diseases, particularly Niemann-Pick Disease Type C, and is conducting several clinical trials for its lead candidate, Trappsol® Cyclo™.
Cyclo Therapeutics has priced an underwritten public offering of 2,500,000 units at $5.00 each, aiming for gross proceeds of $12.5 million. Each unit comprises one share of common stock and one warrant, both expected to trade on Nasdaq under symbols CYTH and CYTHW starting December 9, 2020. Concurrently, a reverse stock split of 1-for-100 will take effect, adjusting share count and pricing. The offering's closing is anticipated on December 11, 2020, subject to standard conditions. The underwriters also hold an option to purchase additional shares to cover any over-allotments.